We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
165 hedge funds and large institutions have $1.6B invested in Esperion Therapeutics in 2017 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 49 increasing their positions, 51 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
57% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 28
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
32% more capital invested
Capital invested by funds: $1.21B → $1.6B (+$385M)
10% more funds holding
Funds holding: 150 → 165 (+15)
5% more call options, than puts
Call options by funds: $51.9M | Put options by funds: $49.2M
4% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 51
1.29% less ownership
Funds ownership: 94.04% → 92.75% (-1.3%)
Holders
165
Holders Change
+15
Holders Change %
+10%
% of All Funds
3.74%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.18%
New
44
Increased
49
Reduced
51
Closed
28
Calls
$51.9M
Puts
$49.2M
Net Calls
+$2.65M
Net Calls Change
+$22.4M
Top Buyers
| 1 |
Millennium Management
New York
|
+$19.1M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$17.3M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$16.2M |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$14.3M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$12.4M |
